U.S. markets open in 2 hours 5 minutes

Fresenius Medical Care AG & Co. KGaA (FME.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
57.38-0.32 (-0.55%)
As of 1:09PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close57.70
Bid57.36 x 38700
Ask57.38 x 105300
Day's Range57.14 - 58.16
52 Week Range53.50 - 79.96
Avg. Volume917,010
Market Cap16.805B
Beta (5Y Monthly)0.96
PE Ratio (TTM)14.49
EPS (TTM)3.96
Earnings DateMay 06, 2021
Forward Dividend & Yield1.20 (2.08%)
Ex-Dividend DateAug 28, 2020
1y Target Est80.61
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2020 Earnings Call Transcript
      Motley Fool

      Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2020 Earnings Call Transcript

      FMS earnings call for the period ending December 31, 2020.

    • Benzinga

      Recap: Fresenius Medical Care Q4 Earnings

      Shares of Fresenius Medical Care (NYSE:FMS) rose 0.0% after the company reported Q4 results. Quarterly Results Earnings per share fell 50.00% year over year to $0.76, which missed the estimate of $0.77. Revenue of $5,246,000,000 higher by 2.26% from the same period last year, which missed the estimate of $6,000,000,000. Guidance Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 23, 2021 View more earnings on FMS Time: 09:30 AM ET Webcast URL: https://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=9256167&linkSecurityString=d6077a4d9 Technicals 52-week high: $46.55 Company's 52-week low was at $29.17 Price action over last quarter: down 6.85% Company Overview Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients in roughly 4,000 clinics across the globe as of December 2019. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Toshiba Up 17% on Plan to Join Tokyo Exchange’s Top Section

      Toshiba Up 17% on Plan to Join Tokyo Exchange’s Top Section

      (Bloomberg) -- Toshiba Corp.’s shares surged the most in three years after the company said it will return to the first section of the Tokyo and Nagoya stock exchanges following an extended absence.The stock briefly touched its daily upper limit and closed 17% higher at 3,460 yen ($33) in Tokyo on Monday, the biggest gain since summer 2017. The move, set for Jan. 29, means the company’s shares will be added to market indexes so domestic active funds can buy the stock, Atul Goyal, senior analyst at Jefferies, wrote in a report describing it as “inexpensive.”Toshiba was demoted to the second section of both exchanges in August 2017 and narrowly avoided a delisting as multibillion-dollar losses at its Westinghouse U.S. nuclear unit pushed liabilities beyond its level of assets. It was forced to sell its prized semiconductor business and take an infusion of cash from a large contingent of activist shareholders. The writedowns and accounting scandals triggered a management shakeup and the appointment of Nobuaki Kurumatani, an outsider, to the post of chief executive officer.Read more: Toshiba Again Seeks Acquisitions After String of Deal FlopsMoving up to TSE-1 will allow Toshiba to rejoin the Topix index on the last trading day of next month, at the market close on Feb. 25, said Travis Lundy, a special-situations analyst who writes for Smartkarma. The inclusion will require passive funds to buy 58 million shares, or 13% of outstanding stock, he estimated.“A Topix inclusion of this size is a rare species,” Lundy wrote in a report. “Long-suffering activists may rejoice. This creates liquidity for a partial exit.”Kurumatani in December signaled Toshiba is ready to again pursue acquisitions and business expansion, though in a more circumspect and cautious manner than previously. He also reaffirmed Toshiba’s intention of unloading its stake in former flash memory unit Kioxia, which he said no longer fit with his company’s remaining businesses.“One thing that changed is that I’m in charge now,” the CEO said in an interview with Bloomberg News. “The board is also applying very stringent standards to acquisitions. It’s a completely different company when it comes to the rigor brought to thinking about and screening deals.”(Updates with closing shares in second paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.